Abstract Number: 1734 • 2017 ACR/ARHP Annual Meeting
CXCR5+ CD4 T Cells Signature Differentiates Takayasu Arteritis from Giant Cell Arteritis
Background/Purpose: To compare microarray gene analysis of patients with Giant cell arteritis to patients with Takayasu arteritis. Methods: We performed comparative microarray gene analysis of…Abstract Number: 790 • 2017 ACR/ARHP Annual Meeting
Pre-Clinical Evidences of Immunomodulatory Activities of Tuftsin-Phosphorylcholine on Samples from Patients with Giant Cell Arteritis in Comparison to Corticosteroids
Background/Purpose: Tuftsin-PhosphorylCholine (TPC) is a novel bi-specific molecule which has shown immunomodulatory effects in experimental mouse models of lupus, colitis and arthritis but data in…Abstract Number: 2932 • 2017 ACR/ARHP Annual Meeting
mTOR Pathway Is Activated in Endothelial Cells from Patients with Takayasu Arteritis and Is Modulated By Serum IgG
Background/Purpose: Takayasu arteritis (TA) and giant cell arteritis (GCA) are large-vessel vasculitis characterized by vascular remodelling involving endothelial cells (ECs) and vascular smooth muscle cells,…Abstract Number: 866 • 2016 ACR/ARHP Annual Meeting
Perivascular Inflammation in Temporal Artery Biopsies That Are Negative for Arteritis: Incidental or Harbinger?
Background/Purpose: The diagnosis of giant cell arteritis (GCA) by temporal artery (TA) biopsy requires pathologic identification of arterial inflammation, usually with giant cells. However, some…Abstract Number: 2939 • 2016 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-Analysis
Risk of Venous Thromboembolism in Patients with Systemic Vasculitides: A Systematic Review and Meta-analysis Background/Purpose: Venous thromboembolism (VTE) is a common medical problem with a…Abstract Number: 867 • 2016 ACR/ARHP Annual Meeting
Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Background/Purpose:Abstract Number: 3044 • 2016 ACR/ARHP Annual Meeting
Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a vascular inflammatory disease involving large and medium sized arteries, particularly the cranial vessels. Inflammation-induced vascular remodeling leads to…Abstract Number: 873 • 2016 ACR/ARHP Annual Meeting
Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis. The pathogenesis of GCA remains incompletely understood. Current evidence suggests that dendritic…Abstract Number: 3182 • 2016 ACR/ARHP Annual Meeting
Attenuation of Fluorine-18-Fluorodeoxyglucose Uptake in Large Vessel Giant Cell Arteritis after Short-Term High-Dose Steroid Treatment – a Diagnostic Window of Opportunity
Background/Purpose: Fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT is, due to its excellent diagnostic accuracy[1], increasingly used to diagnose large vessel GCA (LV-GCA). However, PET/CT is not always readily…Abstract Number: 880 • 2016 ACR/ARHP Annual Meeting
Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Background/Purpose: A key unmet need in the monitoring of disease activity in large vessel vasculitides (LVV), i.e., giant cell arteritis (GCA) and Takayasu arteritis…Abstract Number: 3183 • 2016 ACR/ARHP Annual Meeting
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial
Background/Purpose: As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) of tocilizumab (TCZ) in giant cell arteritis (GCA) showed…Abstract Number: 884 • 2016 ACR/ARHP Annual Meeting
Health-Related Quality of Life in Giant Cell Arteritis
Background/Purpose: To evaluate health-related quality of life (HRQoL) in a large cohort of patients with giant cell arteritis (GCA) as measured by the 36-item…Abstract Number: 3197 • 2016 ACR/ARHP Annual Meeting
Ultrasound Definitions for Cranial and Large Vessel Giant Cell Arteritis: Results of a Reliability Exercise on Images and Videos of the Omeract Ultrasound Large Vessel Vasculitis Task Force
Background/Purpose: By a Delphi process, the OMERACT Ultrasound (US) large vessel vasculitis task force has recently defined the US appearance of normal temporal arteries…Abstract Number: 894 • 2016 ACR/ARHP Annual Meeting
Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?
Background/Purpose: The initial suspicion of Giant cell arteritis (GCA) is often made in the setting of primary care or casualty by a non-rheumatologist. Whilst temporal…Abstract Number: 897 • 2016 ACR/ARHP Annual Meeting
Discordance Rates of Bilateral Temporal Artery Biopsies: A Retrospective Analysis
Background/Purpose: Previous retrospective studies have suggested that simultaneous bilateral temporal artery biopsy (TAB) may lead to increased detection rates of giant cell arteritis (GCA). The term…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 32
- Next Page »